- Home
- MKZR vs COEP Comparison
MKZR vs COEP Comparison
Compare MKZR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- COEP
- Stock Information
- Founded
- MKZR 2012
- COEP 2017
- Country
- MKZR United States
- COEP United States
- Employees
- MKZR N/A
- COEP N/A
- Industry
- MKZR
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MKZR
- COEP Health Care
- Exchange
- MKZR Nasdaq
- COEP Nasdaq
- Market Cap
- MKZR 31.4M
- COEP 32.4M
- IPO Year
- MKZR N/A
- COEP N/A
- Fundamental
- Price
- MKZR $1.93
- COEP $10.52
- Analyst Decision
- MKZR
- COEP
- Analyst Count
- MKZR 0
- COEP 0
- Target Price
- MKZR N/A
- COEP N/A
- AVG Volume (30 Days)
- MKZR 197.0K
- COEP 109.2K
- Earning Date
- MKZR 01-01-0001
- COEP 03-25-2025
- Dividend Yield
- MKZR 15.54%
- COEP N/A
- EPS Growth
- MKZR N/A
- COEP N/A
- EPS
- MKZR N/A
- COEP N/A
- Revenue
- MKZR $23,087,751.00
- COEP N/A
- Revenue This Year
- MKZR N/A
- COEP N/A
- Revenue Next Year
- MKZR N/A
- COEP N/A
- P/E Ratio
- MKZR N/A
- COEP N/A
- Revenue Growth
- MKZR 57.39
- COEP N/A
- 52 Week Low
- MKZR $1.05
- COEP $2.31
- 52 Week High
- MKZR $5.50
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- COEP 48.65
- Support Level
- MKZR N/A
- COEP $9.27
- Resistance Level
- MKZR N/A
- COEP $12.95
- Average True Range (ATR)
- MKZR 0.00
- COEP 1.59
- MACD
- MKZR 0.00
- COEP -0.33
- Stochastic Oscillator
- MKZR 0.00
- COEP 38.56
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.